Roche Holding Ltd · SIX:RO
Roche — Investor Day (March 2021)
72 slides from Roche's investor day presentation, Mar 23, 2021
Slide 1: Roche Diagnostics Investor Day 2021
Roche Diagnostics Investor Day 2021 23rd March 2021
Slide 2: Welcome
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche Diagnostics Investor Day 2021 Welcome Karl Mahler | Head of Investor Relations and Roche Group Planning Previous Page Next Page
Slide 3: Agenda
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Agenda Welcome Karl Mahler, Head of investor Relations and Roche Group Planning Strategy & Organization Thomas Schinecker, CEO Diagnostics 2.00-2.40pm Diagnos
Slide 4: IVD Market has seen consolidation
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing IVD Market has seen consolidation Roche staying in the lead IVD market size1 (in bnCHF) CAGR2 63 - Market Share in % - +4% Insights 42 Other 48% • Roche stayi
Slide 5: Strategy & Organization
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche Diagnostics Investor Day 2021 Strategy & Organization Thomas Schinecker | CEO Diagnostics Previous Page Next Page
Slide 6: Roche clear leader in growing IVD market
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche clear leader in growing IVD market 14 billion CHF revenue in 20201 19% share as IVD market leader1 23.4 billion tests1 #1 in Clinical Chemistry & Immuno
Slide 7: Global transformation exercise
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Global transformation exercise Develop strategic options and recommendations Strategic topics ... ... addressed by cross-functional teams of experts 1 Custome
Slide 8: Healthcare objectives
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Healthcare objectives Improve patient outcomes and reduce costs Healthcare systems aim to… Improve outcomes Better outcomes and better social and economic ben
Slide 9: Patient journey
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Patient journey Optimising care along the patient journey Prevention Diagnosis Treatment Monitoring Core Lab: ECL results Key unmet needs (e.g. markers, decis
Slide 10: Strategy and financial ambitions
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Strategy and financial ambitions Improve care along patient Improve patients’ lives via ‘OneRoche journeys Approach’ Outcomes Enable confident healthcare Buil
Slide 11: Organizational transformation enabling new strategic priorities
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Organizational transformation enabling new strategic priorities Simplification and focus through customer & function centricity New diagnostics organization R
Slide 12: Changes in regional reporting
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Diagnostics reporting 2021 onwards Moving from business to customer areas and adjusting regions Old New Changes in customer areas reporting Changes in regiona
Slide 13: Funding the Strategy
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Funding the Strategy Shifting investments into strategic priorities Fund strategic priorities: Re-invest in Free resources strategic focus • Medical value sol
Slide 14: Diagnostics solutions
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Diagnostics solutions Deliver medical value on integrated testing solutions Improve care along patient journeys Outcomes Enable confident healthcare Costs dec
Slide 15: Diagnostics Solutions strategic priorities
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Diagnostics Solutions strategic priorities Developing comprehensive solutions for our customers Focus on customer solution and experience Differentiators Core
Slide 16: Healthcare decision support solutions
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Healthcare decision support solutions Enable confident healthcare decisions Improve care along patient journeys Outcomes Enable confident healthcare Costs dec
Slide 17: Roche Information Solutions strategic priorities
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche Information Solutions strategic priorities Supporting healthcare decisions Focus on customer solutions and experience Differentiators Lab Insights Platf
Slide 18: Disease management solutions
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Disease management solutions Improve care along patient journeys Value-based solutions Improve care along patient journeys Outcomes Enable confident healthcar
Slide 19: Disease management solutions: orchestration along patient journey
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Disease management solutions Unlocking value through orchestration along patient journey Others IVD test Clinical Algorithms Diagnostic solutions Patient Pati
Slide 20: Strategy and financial ambitions
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Strategy and financial ambitions Improve care along patient Improve patients’ lives via ‘OneRoche journeys Approach’ Outcomes Enable confident healthcare Buil
Slide 21: Diagnostics Solutions & Customer Areas
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche Diagnostics Investor Day 2021 Diagnostics Solutions & Customer Areas Ann Costello | Global Head Roche Diagnostics Solutions Previous Page Next Page
Slide 22: Diagnostics solutions: Strategic priorities
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Diagnostics solutions: Strategic priorities Providing comprehensive solutions for our key customer segments Customer Core Lab Molecular Lab1 Pathology Lab1 Po
Slide 23: Diagnostics solutions: four distinct pillars
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Diagnostics solutions: Strategic priorities Achieving differentiation based on four distinct pillars Diagnostics Medical value Digitalization Market access ef
Slide 24: SARS-CoV-2 diagnostics portfolio
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing SARS-CoV-2 diagnostics portfolio1 Comprehensive portfolio of tests and digital solutions Clinical Labs Near Patient • cobas® SARS-CoV-2 Launched • cobas® SARS
Slide 25: Investing CHF >600m to increase supply chain capacities
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Investing CHF >600m to increase supply chain capacities Driving to unprecedented volume in record time Consumables Reagents • 60 new manufacturing lines • 20
Slide 26: Molecular Lab installed base
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Molecular Lab installed base We significantly increased our footprint in the market Installed base for cobas® 6800/8800 2021 aspiration +42% ~1,200 ~800 2018
Slide 27: Levering our installed base in the future
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Levering our installed base in the future Enabler to sell high medical value biomarkers Further consolidation of labs Our aim to bring more & customer prefere
Slide 28: Roche molecular solutions portfolio
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche molecular solutions portfolio GenMark1 Diagnostics fills the portfolio gap in molecular multiplexing Throughput cobas® Liat® GenMark cobas® 58002 cobas®
Slide 29: Research & Development
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche Diagnostics Investor Day 2021 Research & Development Palani Kumaresan | Head of Research & Development Previous Page Next Page
Slide 30: Our commitment to innovation
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Our commitment to innovation We invest more in our IVD portfolio than other companies 125 CHF million per month 1.5 billion CHF 12% of revenue 0.7 billion CHF
Slide 31: R&D efficiencies
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing R&D efficiencies Implementing our new strategy will improve productivity Increase organizational Improve effectiveness project delivery • Improved standardiza
Slide 32: Strategy around menu expansion
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Strategy around menu expansion Broadest menu and most differentiated medical value solutions Medical value solutions2 that are differentiated, based on clinic
Slide 33: Approach to medical value solutions
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Approach to medical value solutions Multi-modal, multi-parametric approach along continuum of care Disease areas Cardio- Infectious Women’s Oncology CNS metab
Slide 34: A broad portfolio of solutions across the care continuum
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing A broad portfolio of solutions across the care continuum Disease Therapy selection Indication Screening Diagnosis Risk stratification area / monitoring Atrial
Slide 35: Recent Breakthrough Device Designations
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Recent Breakthrough Device Designations (BDDs) Leading innovation recognized by the FDA Infectious diseases Oncology Women’s health CNS Others cobas® EBV: EBV
Slide 36: Key launches 2021
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Key launches 2021 Area Product Description Market1 cobas® pure integrated solutions Low-to-medium volume SWA CE Core Lab cobas® pro integrated solutions New h
Slide 37: Q&A
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Q&A 37 Previous Page Next Page
Slide 38: Systems
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche Diagnostics Investor Day 2021 Systems Benjamin Lilienfield | Life Cycle Leader Systems Previous Page Next Page
Slide 39: Largest installed base worldwide with significant growth in 2020
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Largest installed base worldwide with significant growth in 2020 +9% cobas® 4000/6000/8000 +23% Lab SW solutions +42% cobas® 6800/8800 +10% cobas® 4800 +10% +
Slide 40: cobas 6800/8800 menu expansion driving growth in molecular
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing cobas® 6800/8800 menu expansion driving growth in molecular Further growing the installed base in 2021 Antimicrobial Donor Screening Blood Borne Disease Sexua
Slide 41: Roche Serum Work Area menu
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche Serum Work Area menu Broadest menu on one integrated platform Breadth of assay menu Launched in 2020 & upcoming launches in 2021 250 231 Immuno chemistr
Slide 42: New systems launches in 2021
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing New systems launches in 2021 Enabling comparable results in different size laboratories Throughput cobas® pure1 cobas® pro cobas® pro (high throughput) Improv
Slide 43: Live Stream Demo
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Live Stream Demo 43 Previous Page Next Page
Slide 44: New innovations driving market access
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing New innovations driving market access Mass Spectrometry Emerging Market Analyzer First fully integrated mass spectrometry Routing testing in remote areas ● In
Slide 45: Infectious Diseases
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche Diagnostics Investor Day 2021 Infectious Diseases Michael Hombach | Global Clinical Leader Infectious Diseases Previous Page Next Page
Slide 46: Infectious Diseases are still causing global harm
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Infectious Diseases are still causing global harm Cause of death globally (millions per year)1,2 Cardiovascular diseases 18 >2tn CHF COVID-19 Infectious disea
Slide 47: Pathogen, immunity and host belong together
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Pathogen, immunity and host belong together Developing comprehensive disease-based solutions for patients PATHOGEN Bacteria, Viruses, Fungi, Parasites IMMUNIT
Slide 48: Medical use cases across the patient journey
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing What are the medical use cases across the patient journey ? e.g. SARS-CoV-2 e.g. SARS-CoV-2 antibodies PCR and Antigen assays: Antibody assays: e.g. cobas® SA
Slide 49: Global emerging and re-emerging infectious diseases
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Global emerging and re-emerging infectious diseases 49 Source: National Institute of Allergy and Infectious Diseases (NAID) 2017 Previous Page Next Page
Slide 50: Roche infectious diseases pipeline
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche infectious diseases pipeline Holistic portfolio coverage is a key medical value Pregnancy + Antimicrobial Viral Hepatitis + STDs Respiratory Vector Born
Slide 51: Systematically addressing areas of unmet medical needs
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche infectious diseases pipeline Systematically addressing areas of unmet medical needs Tuberculosis Sepsis Dengue Fever Antimicrobial Lyme Disease Resistan
Slide 52: Molecular Diagnostics respiratory multiplex panel
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Molecular Diagnostics respiratory multiplex panel Breaking the barriers of syndromic testing Empowered by TAGS 5 channels = 15 targets • High unmet medical ne
Slide 53: Quote from Peter C. Doherty
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing “I share Alfred Nobel's conviction that war is the greatest of all human disasters. Infectious disease runs a good second.” Peter C. Doherty, 1996 Nobel Prize
Slide 54: Cardiology
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche Diagnostics Investor Day 2021 Cardiology Andre Ziegler | Global Clinical Leader Cardiology Previous Page Next Page
Slide 55: Cardiovascular disease is #1 killer in the world
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Cardiovascular disease is #1 killer in the world Cause of 18 million deaths globally per year1 Disease Burden Index Cardiovascular disease major Cardiac cost
Slide 56: Roche is an IVD market leader in cardiovascular diseases
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche is an IVD market leader in cardiovascular diseases Highest benefit class and evidence level in major cardiac guidelines Core Lab cardiovascular market s
Slide 57: Leading coronary artery disease
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Leading coronary artery disease Setting new standards of care in diagnosing heart attacks Elecsys® Troponin T-high sensitive (TnT-hs) test New data on cardiac
Slide 58: Transforming diagnostics in heart failure
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Transforming diagnostics in heart failure Type-2 diabetes: Identifying heart failure early to improve outcome Stages of heart failure1 New NT-proBNP intended
Slide 59: Improving disease management to reduce strokes
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Improving disease management to reduce strokes Innovation on-market and pipeline for atrial fibrillation Cardiac Screening Diagnosis Risk stratification Thera
Slide 60: Cardiovascular disease solutions
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Cardiovascular disease solutions New solutions to impact medical practice Launch new intended uses New patient in 2021 population • TnT-hs in non-cardiac surg
Slide 61: Oncology
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche Diagnostics Investor Day 2021 Oncology Jill German | Global Head of Pathology Lab Previous Page Next Page
Slide 62: Global cancer burden projected to increase
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Global cancer burden projected to increase Significant impact to both human lives and world economy 62 1 Disease burden: Impact of a health problem as measure
Slide 63: The field of oncology is evolving and increasing in complexity
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing The field of oncology is evolving and increasing in complexity Driving the need for novel diagnostic solutions Oncology market New diagnostics and is rapidly
Slide 64: Supporting patient journeys with our oncology portfolio
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Supporting patient journeys with our oncology portfolio Sales of oncology reagents surpassing CHF 1.8 bn in 2020 Screening Diagnosis & Classification Prognosi
Slide 65: Supporting patient journeys with our oncology pipeline
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Supporting patient journeys with our oncology pipeline Pharma partner of choice, driving personalised healthcare Screening Diagnosis & Classification Prognosi
Slide 66: Example: Our comprehensive solution for lung cancer
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Example: Our comprehensive solution for lung cancer Innovating clinical decision making and improving patient care Lung Diagnosis & Classification Therapy sel
Slide 67: Integrated oncology decision support
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Integrated oncology decision support AI-enabled digital solutions for informed, efficient patient management NAVIFY® Digital Pathology NAVIFY® NAVIFY® Flatiro
Slide 68: Q&A
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Q&A 68 Previous Page Next Page
Slide 69: Closing
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Roche Diagnostics Investor Day 2021 Closing Thomas Schinecker | CEO Diagnostics Previous Page Next Page
Slide 70: Setting up Diagnostics for a sustainable and successful future
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Setting up Diagnostics for a sustainable and successful future Healthcare is shifting to reward improved patient outcomes at reduced cost of care Point of dep
Slide 71: Diagnostics investor day summary
Welcome Strategy & Organization Dia Solutions & Customer Areas Research & Development Systems Infectious Diseases Cardiology Oncology Closing Diagnostics investor day summary Grow our market share Invest in strategic priorities ? • Larger installed base and new systems • Increase productivity by sim
Slide 72: Doing now what patients need next
Doing now what patients need next 72